This Article Full Text Full Text (PDF) All Versions of this Article: 110/14/2053    most recent 01.CIR.0000143234.51796.A9v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buerkle, M. A. Articles by Krötz, F. Search for Related Content PubMed PubMed Citation Articles by Buerkle, M. A. Articles by Krötz, F. Related Collections Animal models of human disease Arterial thrombosis Aggregation Platelets Endothelium/vascular type/nitric oxide

(Circulation. 2004;110:2053-2059.)
© 2004 American Heart Association, Inc.

Vascular Medicine

Selective Inhibition of Cyclooxygenase-2 Enhances Platelet Adhesion in Hamster Arterioles In Vivo

Martin A. Buerkle, MD; Selim Lehrer, MS; Hae-Young Sohn, MD; Peter Conzen, MD; Ulrich Pohl, MD; Florian Krötz, MD

From the Institute of Physiology (M.A.B., S.L., U.P., F.K.), the Clinic of Anaesthesiology (M.A.B., P.C.), and the Department of Cardiology (H.-Y.S., F.K.), Medizinische Poliklinik-Innenstadt, Ludwig-Maximilians University, Munich, Germany.

Correspondence to Florian Krötz, MD, Institute of Physiology and Cardiology Division, Medizinische Poliklinik-Innenstadt, Ludwig-Maximilians University, Ziemssenstr 1, 80336 Munich, Germany. E-mail fkroetz{at}lmu.de

Received April 22, 2004; de novo received June 16, 2004; accepted July 7, 2004.

Background— Selective inhibitors of cyclooxygenase-2 (Cox-2) are reported to cause cardiovascular side effects in patients at risk. However, direct proof of prothrombotic effects of these drugs is lacking. We investigated in the microcirculation in vivo whether selective inhibition of Cox-2 induces platelet activation.

Methods and Results— The behavior of fluorescence-labeled human platelets was studied in hamster arterioles (dorsal skinfold chamber) by intravital microscopy. Transient platelet–vessel wall interactions (PVWIs), firm platelet adhesion to the vessel wall, and vessel occlusion after FeCl₃-induced wall injury were analyzed as platelet activation parameters. In vitro experiments in human umbilical vein endothelial cells (HUVECs) were performed to assess specific effects of Cox-2 inhibition on platelet adhesion under shear stress (16 dyn/cm²) and on endothelial release of 6-ketoprostaglandin (PG) F₁. Selective inhibition of Cox-2 (NS-398, 0.5 mg/kg) increased platelet adhesion to the vessel wall in vivo (11.9±3.9 platelets/mm²; controls, 1.4±1.4 platelets/mm², P<0.05) and platelet adhesion after ADP stimulation in vitro. PVWIs were significantly enhanced in NS-398–treated animals, which were reduced by platelet pretreatment with aspirin (5 mg/kg) or iloprost (1 nmol/L). Inhibition of Cox-2 reduced levels of 6-keto-PGF₁ in vivo and in HUVEC supernatants. Time to occlusion after vessel wall injury was significantly shortened by NS-398 (125.4±13.6 seconds in NS-398–treated animals versus 270.8±46 seconds in controls; P<0.01).

Conclusions— Selective inhibition of Cox-2 reduces 6-keto-PGF₁ endothelial release, increases PVWIs, and increases firm platelet adhesion in hamster arterioles. Moreover, it leads to faster occlusion of damaged microvessels. Thus, selective inhibition of Cox-2 may trigger thrombotic events by diminishing the antiplatelet properties of the endothelium.

Key Words: aspirin • prostaglandins • platelets • thrombosis • endothelium

This article has been cited by other articles:

				F. Krotz, N. Hellwig, M. A. Burkle, S. Lehrer, T. Riexinger, H. Mannell, H.-Y. Sohn, V. Klauss, and U. Pohl A sulfaphenazole-sensitive EDHF opposes platelet-endothelium interactions in vitro and in the hamster microcirculation in vivo Cardiovasc Res, October 4, 2009; (2009) cvp301v2. [Abstract] [Full Text] [PDF]

				F. Krotz Putting the vasoactive effects of COX-2-derived prostanoids into clinical perspective Cardiovasc Res, February 1, 2009; 81(2): 240 - 241. [Full Text] [PDF]

				M. W. Laschke and M. D. Menger In vitro and in vivo approaches to study angiogenesis in the pathophysiology and therapy of endometriosis Hum. Reprod. Update, July 1, 2007; 13(4): 331 - 342. [Abstract] [Full Text] [PDF]

				G. Salinas, U. C. Rangasetty, B. F. Uretsky, and Y. Birnbaum The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame Journal of Cardiovascular Pharmacology and Therapeutics, June 1, 2007; 12(2): 98 - 111. [Abstract] [PDF]

				P. Borgdorff, G. J. Tangelder, and W. J. Paulus Cyclooxygenase-2 Inhibitors Enhance Shear Stress-Induced Platelet Aggregation J. Am. Coll. Cardiol., August 15, 2006; 48(4): 817 - 823. [Abstract] [Full Text] [PDF]

				E. Fosslien Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 347 - 385. [Abstract] [Full Text] [PDF]